Sunrun Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 192.34%
- Profit Growth 82.00%
- Ebitda 154.84%
- Net Worth -5.89%
- Total Assets 175.84%
About Sunrun Pharmaceuticals
Sunrun Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 December 2015 (Nine years and two months 19 days old ). Its registered office is in Bilaspur, Chattisgarh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.00 M.
Sangeeta Banerjee and Sanjit Banerjee serve as directors at the Company.
Company Details
- Location
Bilaspur, Chattisgarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397CT2015PTC001979
- Company No.
001979
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Dec 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Who are the key members and board of directors at Sunrun Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangeeta Banerjee  | Director | 07-Dec-2015 | Current |
| Sanjit Banerjee | Director | 07-Dec-2015 | Current |
Financial Performance of Sunrun Pharmaceuticals.
Sunrun Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 192.34% increase. The company also saw a substantial improvement in profitability, with a 82% increase in profit. The company's net worth dipped by a decrease of 5.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunrun Pharmaceuticals?
In 2017, Sunrun Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Sep 2024 | Canara Bank | ₹1.00 M | Open |
How Many Employees Work at Sunrun Pharmaceuticals?
Unlock and access historical data on people associated with Sunrun Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunrun Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunrun Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.